PepGen Inc. (NASDAQ:PEPG) to Post Q1 2025 Earnings of ($0.67) Per Share, Wedbush Forecasts

PepGen Inc. (NASDAQ:PEPG) – Analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for PepGen in a research note issued to investors on Wednesday, May 15th. Wedbush analyst L. Chico forecasts that the company will post earnings per share of ($0.67) for the quarter. Wedbush currently has a “Outperform” rating and a $20.00 target price on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.89) per share. Wedbush also issued estimates for PepGen’s Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.60) EPS and Q4 2025 earnings at ($0.61) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $26.00 price target on shares of PepGen in a report on Wednesday.

PepGen Stock Down 1.2 %

PepGen stock opened at $13.65 on Thursday. The business’s 50-day simple moving average is $13.18 and its 200 day simple moving average is $10.04. The stock has a market cap of $442.12 million, a price-to-earnings ratio of -4.12 and a beta of 1.64. PepGen has a 12-month low of $3.72 and a 12-month high of $17.51.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.01) by $0.19.

Hedge Funds Weigh In On PepGen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PEPG. Acadian Asset Management LLC bought a new position in PepGen during the first quarter worth about $30,000. Allspring Global Investments Holdings LLC bought a new position in PepGen during the third quarter worth about $33,000. Rathbones Group PLC bought a new position in PepGen during the third quarter worth about $315,000. Adage Capital Partners GP L.L.C. boosted its holdings in PepGen by 18.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 680,000 shares of the company’s stock worth $3,454,000 after buying an additional 105,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in PepGen by 68.0% during the first quarter. Vanguard Group Inc. now owns 850,445 shares of the company’s stock worth $12,502,000 after buying an additional 344,266 shares during the last quarter. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.